Every material Form 8-K ENANTA PHARMACEUTICALS INC has filed with the SEC since August 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Enanta Pharmaceuticals said the Unified Patent Court of the European Union ruled on October 29, 2026 that its European Patent No. EP 4 051 265 is invalid and that its infringement action against Pfizer was unfounded. The ruling ends Enanta's infringement claim over Pfizer's Paxlovid sales in the 18 participating EU member states, which the filing does not quantify.
Court decision released October 29, 2026, following a hearing held September 29, 2026
UPC concluded the '265 Patent is invalid, responding to Pfizer's counterclaim for revocation
Court also found the infringement action unfounded in light of the validity decision
Filing does not state any financial impact, damages, or next steps
Enanta Pharmaceuticals said CEO Jay R. Luly, Ph.D., 70, will retire by February 1, 2027, after 23 years leading the company, and will serve as a strategic advisor for the rest of 2027. The board has started a search for a successor, considering both internal and external candidates, and named Tara L. Kieffer, Ph.D., to the newly created role of Chief Operating Officer. The filing does not include financial results, so the changes are mainly about management succession for shareholders.
Jay R. Luly, Ph.D., age 70, will retire as President and CEO by February 1, 2027, after 23 years with the company
Luly will continue as a strategic advisor for the remainder of 2027; the company expects to enter an agreement for this role
The board is searching for a successor, considering internal and external candidates
Tara L. Kieffer, Ph.D., age 48, was appointed Chief Operating Officer on October 28, 2026; she joined Enanta in 2020 as Chief Product Strategy Officer
Enanta Pharmaceuticals reported results for its fiscal third quarter ended June 30, 2026. Revenue fell to $14.4 million from $18.3 million a year earlier, mainly on lower AbbVie HCV sales, and the net loss widened to $19.5 million from $18.3 million, although the per-share loss narrowed to $0.67 from $0.85 on a higher share count.
Revenue was $14.4 million versus $18.3 million a year earlier, reflecting lower reported AbbVie HCV sales of MAVYRET/MAVIRET.
Net loss was $19.5 million, or $0.67 per diluted share, versus a net loss of $18.3 million, or $0.85 per diluted share, a year earlier.
Cash, cash equivalents and marketable securities totaled $211.5 million at June 30, 2026; the company expects funds to last into fiscal 2029.
RESOLVE, a registrational Phase 2b/3 trial of zelicapavir, is on track to start in the fourth quarter of 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ENANTA PHARMACEUTICALS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →